A5040764520- Chronic Myeloid Leukemia Treatments
- Quinazolinone synthesis and applications
- PARP inhibition in cancer therapy
- HER2/EGFR in Cancer Research
- PI3K/AKT/mTOR signaling in cancer
- Fungal Plant Pathogen Control
- Chronic Lymphocytic Leukemia Research
- DNA Repair Mechanisms
- Colorectal Cancer Treatments and Studies
- Synthesis and biological activity
- Cancer Mechanisms and Therapy
- Radiation Therapy and Dosimetry
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Diet, Metabolism, and Disease
- Diet and metabolism studies
- Radiopharmaceutical Chemistry and Applications
- Cancer, Lipids, and Metabolism
- Energy and Environmental Systems
- Breast Cancer Treatment Studies
- Food Quality and Safety Studies
- Microtubule and mitosis dynamics
- Cancer Treatment and Pharmacology
- Adipokines, Inflammation, and Metabolic Diseases
- 14-3-3 protein interactions
Amorepacific (South Korea)
2021-2025
Seoul National University
2009-2023
AstraZeneca (United Kingdom)
2012-2013
New Generation University College
2013
Hanmi Pharmaceutical (South Korea)
2013
Seoul National University Hospital
2012
Abstract A PARP inhibitor is a rationally designed targeted therapy for cancers with impaired DNA repair abilities. RAD51C paralog of RAD51 that has an important role in the damage response. We found cell lines sensitive to novel oral inhibitor, olaparib, had low levels expression using microarray analysis, and we therefore hypothesized may hamper process, resulting increased sensitivity olaparib. Compared cells normal levels, RAD51C-deficient cancer were more higher proportion underwent...
Abstract Src is a nonreceptor tyrosine kinase involved in the cross-talk and mediation of many signaling pathways that promote cell proliferation, adhesion, invasion, migration, tumorigenesis. Increased activity has been reported types human cancer, including gastric cancer. Therefore, this factor identified as promising therapeutic target for cancer treatments, targeting predicted to have potent effects. We evaluated antitumor effect c-Src/Abl inhibitor, saracatinib (AZD0530), alone or...
Purpose KX-01 is a novel dual inhibitor of Src and tubulin. Unlike previous inhibitors that failed to show clinical benefit during treatment breast cancer, can potentially overcome the therapeutic limitations current through inhibition both The present study further evaluates activity mechanism in vitro vivo. Materials Methods antitumor effect triple negative cancer (TNBC) cell lines was determined by MTT assay. Wound healing immunofluorescence assays were performed evaluate action...
2565 Background: HM781-36B, a novel pan-HER tyrosine kinase inhibitor, showed potent in vitro and vivo antitumor activities for EGFR mutant models including T790M mutation. In the previous 2-weeks on, 1-week off phase I study, maximum tolerated dose (MTD) was determined as 24 mg/day. Phase study with continuous daily dosing schedule conducted to determine recommended (RD), assess effect of food on pharmacokinetics (PK) patients (pts) advanced solid tumors. Methods: Eligible pts had...
Abstract Background: Src is a nonreceptor tyrosine kinase involved in the crosstalk and mediation of many signaling pathways that promote cell proliferation, invasion angiogenesis. Elevation activity has been reported types cancers including gastric cancer (GC) biliary tract (BTC). The purpose this study to evaluate as therapeutic target elaborate biomarkers inhibitor GC BTC. Methods: Ten lines (SNU-1, 5, 16, 216, 601, 620, 638, 668, 719, NCI-N87) 8 (SNU-245, 308, 478, 869, 1079, 1196,...
<p>PDF file - 3250K, Figure S1 Olaparib has variable levels of anti-tumor activity in human cancer cell lines. S2 sensitive lines have different patterns gene expression compared to insensitive S3 PTEN does not affect olaparib sensitivity. S4 RAD51C affects sensitivity S5 over-expression decreases the BT-549 line. S6 induces G2/M cycle arrest and apoptosis S7 depletion increases accumulation DNA damage. S8 tumor tissues. S9 is down-regulated gastric tissues via methylation. Table S1....
<p>PDF file - 176K</p>
<div>Abstract<p>Recently, HER2-directed treatment, such as trastuzumab, has shown clinical benefit in HER2-amplified gastric cancer. On the basis of recent studies about epidermal growth factor receptor (EGFR) or HER2-targeting agents (including gefitinib, lapatinib, and trastuzumab) cancer, potent effects pan-HER inhibitors targeting HER family are anticipated. In this study, we evaluated activity mechanisms PF00299804, an irreversible inhibitor, cancer <i>in...
<div>Abstract<p>Src is a nonreceptor tyrosine kinase involved in the cross-talk and mediation of many signaling pathways that promote cell proliferation, adhesion, invasion, migration, tumorigenesis. Increased Src activity has been reported types human cancer, including gastric cancer. Therefore, this factor identified as promising therapeutic target for cancer treatments, targeting predicted to have potent effects. We evaluated antitumor effect c-Src/Abl inhibitor, saracatinib...
<div>Abstract<p>Recently, HER2-directed treatment, such as trastuzumab, has shown clinical benefit in HER2-amplified gastric cancer. On the basis of recent studies about epidermal growth factor receptor (EGFR) or HER2-targeting agents (including gefitinib, lapatinib, and trastuzumab) cancer, potent effects pan-HER inhibitors targeting HER family are anticipated. In this study, we evaluated activity mechanisms PF00299804, an irreversible inhibitor, cancer <i>in...
<div>Abstract<p>Src is a nonreceptor tyrosine kinase involved in the cross-talk and mediation of many signaling pathways that promote cell proliferation, adhesion, invasion, migration, tumorigenesis. Increased Src activity has been reported types human cancer, including gastric cancer. Therefore, this factor identified as promising therapeutic target for cancer treatments, targeting predicted to have potent effects. We evaluated antitumor effect c-Src/Abl inhibitor, saracatinib...
Abstract Background: Src is a nonreceptor tyrosine kinase involved in the crosstalk and mediation of many signaling pathways that promote cell proliferation, adhesion, invasion, migration, metastasis, angiogenesis, tumorigenesis. Elevation activity has been reported types human cancers. Therefore, promising therapeutic target for treatment However, mechanism inhibition gastric cancers not fully understood yet. Saracatinib an orally active small molecule c-Src/abl inhibitor currently phase II...
Abstract Background: Amphiregulin is a ligand for the epidermal growth factor receptor (EGFR). Human 2 (HER2) shares common signal pathways and forms heterodimer with EGFR. In this study, we investigated effect of amphiregulin on trastuzumab therapy in HER2-positive breast cancer. Methods: We analyzed serum levels by enzyme-linked immunosorbent assay (ELISA) from baseline samples obtained metastatic cancer patients who received first-line plus taxane chemotherapy. addition, vitro experiments...
Abstract Background: The poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib, has been found to have a therapeutic potential for treating cancers that an impaired DNA repair ability. RAD51C reported play essential role in mediated by homologous recombination. In addition, is gene affects human cancer susceptibility, similar BRCA1 and BRCA2. RAD51C-defective can therefore be potentially treated with olaparib because damage induced cannot effectively repaired HR since deficiency interferes...
<p>PDF file - 103K</p>
<p>PDF file - 135K, Treatment of saracatinib in LS174T and SKBR3 cells</p>
<p>PDF file - 173K, Induction of Bim by saracatinib treatment</p>
<p>PDF file - 96K, Downregulation of thymidylate synthase (TS) by saracatinib</p>
<p>PDF file - 215K, mRNA and protein expression level of integrin �8 in gastric cancer cell lines</p>
<p>PDF file - 114K, Chemical structures of investigated molecules in this article</p>
<p>PDF file - 335K</p>